6/2/2021 1:06:02 AM
ObsEva To Present Data From PROLONG Phase 2a Proof-of-concept Study Of Ebopiprant At RCOG Virtual World Congress 2021
5/31/2021 1:40:02 AM
ObsEva Says Shareholders Approved All Board Proposals At 2021 AGM Held On May 28
5/20/2021 1:11:24 AM
ObsEva Reports Final Results From Phase 3 PRIMROSE Program Of Yselty For Uterine Fibroids
5/4/2021 1:24:55 AM
Obseva Completes Enrollment For Phase 3 EDELWEISS 3 Trial Of Yeslty For Moderate To Severe Endometriosis-associated Pain
4/27/2021 1:12:34 AM
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study
3/5/2021 1:09:05 AM
ObsEva FY Net Loss $83.0 Mln Or $1.67/Shr Vs Loss $108.8 Mln Or $2.49/Shr Last Year
1/11/2021 1:57:17 AM
ObsEva Says EMA Validates Yselty MAA For Uterine Fibroids; US NDA Planned For H1'21
1/4/2021 1:05:27 AM
ObsEva Appoints David Renas As CFO And Member Of Company's Executive Committee
11/24/2020 1:12:00 AM
ObsEva Submits Marketing Authorization Application To EMA For YSELTY For Women With Uterine Fibroids
11/16/2020 1:06:30 AM
ObsEva Reports Positive Topline Results Of PROLONG Proof-of-Concept Trial Of Ebopiprant (OBE022) For Preterm Labor